Individualized 6‐mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|1|53-60

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.1, 2018-01, pp. : 53-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Individualized therapy for childhood acute lymphoblastic leukemia

By Raetz Elizabeth A   Bhojwani Deepa   Min Dong-Joon   Carroll William L  

Personalized Medicine, Vol. 2, Iss. 4, 2005-11 ,pp. : 349-361

Future Medicine

Access to resources Recommend Favorite

The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event‐free survival in the NOPHO ALL92 protocol

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 4, 2014-04 ,pp. : 653-658

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment‐related mortality in relapsed childhood acute lymphoblastic leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 4, 2018-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

PEG‐asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 3, 2015-03 ,pp. : 427-433

John Wiley & Sons Inc

Access to resources Recommend Favorite

Childhood acute lymphoblastic leukemia: Integrating genomics into therapy

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3577-3590

John Wiley & Sons Inc

Access to resources Recommend Favorite